Cargando…
The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cells
Mutant TP53 proteins are thought to drive the development and sustained expansion of cancers at least in part through the loss of the wild-type (wt) TP53 tumour suppressive functions. Therefore, compounds that can restore wt TP53 functions in mutant TP53 proteins are expected to inhibit the expansio...
Autores principales: | Wang, Zilu, Hu, Huimin, Heitink, Luuk, Rogers, Kelly, You, Yue, Tan, Tao, Suen, Connie Li Wai, Garnham, Alex, Chen, Hao, Lieschke, Elizabeth, Diepstraten, Sarah T., Chang, Catherine, Chen, Tianwei, Moujalled, Diane, Sutherland, Kate, Lessene, Guillaume, Sieber, Oliver M., Visvader, Jane, Kelly, Gemma L., Strasser, Andreas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10070280/ https://www.ncbi.nlm.nih.gov/pubmed/36739334 http://dx.doi.org/10.1038/s41418-023-01122-3 |
Ejemplares similares
-
Correction to: The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cells
por: Wang, Zilu, et al.
Publicado: (2023) -
Discussion of some ‘knowns’ and some ‘unknowns’ about the tumour suppressor p53
por: Lieschke, Elizabeth, et al.
Publicado: (2018) -
APR-246 Enhances Colorectal Cancer Sensitivity to Radiotherapy
por: Xie, Xuqin, et al.
Publicado: (2023) -
APR-246 increases tumor antigenicity independent of p53
por: Michels, Judith, et al.
Publicado: (2023) -
Lymphoma cells lacking pro-apoptotic BAX are highly resistant to BH3-mimetics targeting pro-survival MCL-1 but retain sensitivity to conventional DNA-damaging drugs
por: Diepstraten, Sarah T., et al.
Publicado: (2023)